All posts related to "SEBs"

Let BC PharmaCare hear “Your Voice” on etanercept SEB

Stick man holding megaphoneBC PharmaCare is looking for your input on etanercept SEB for the treatment of rheumatoid arthritis and ankylosing spondylitis

Etanercept SEB is a subsequent entry biologic version of etanercept (Enbrel). Etanercept SEB is used for treating people with moderate to severe rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and works by targeting the tumor necrosis factor alpha (TNFA) molecule. It is given by subcutaneous injection.

A SEB needs to have the same mechanism of action as the originator biologic it was compared to, which means it should work in a similar way. Health Canada defines SEBs as a “biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug.” Continue reading

FDA proposed new naming policies for biosimilar drugs for RA

Yellow and Purple pills in palm of handThe Food and Drug Administration (FDA) has proposed new naming policies for the distinct naming of biosimilars and biologics for rheumatoid arthritis treatment. The new draft guidance is called Nonproprietary Naming of Biological Products: Guidance for Industry and is available to view here.

Under the new policies, which will be designated and enforced by the FDA, separate and distinctive names will be required when it comes to biosimilars and biologic drugs. This will ensure that pharmaceutical companies are following regulations and will remain compliant when it comes to the naming and marketing of biosimilar medications.  Continue reading

ACE présente les « Contenus partageables JointHealth™ »

« Contenus partageables JointHealth™ » – Découvrez-les, partagez-les !

Que ce soit un contenu infographique, une vidéo ou une brochure en ligne, le comité ACE est toujours à la recherche de nouvelles façons conviviales de partager l’info avec ses membres, abonnés et visiteurs en ligne pour leur permettre de se tenir au courant des sujets les plus populaires et des enjeux liés à l’arthrite et aux soins de santé. En lançant notre nouveau programme, les contenus partageables JointHealth™, nous vous offrons tout cela en un seul endroit pratique. Chaque contenu partageable JointHealth™ traitera d’un thème présentant un intérêt particulier identifié par vous, nos lecteurs et visiteurs en ligne.

Les deux premiers contenus partageables JointHealth™ traitent :

  • Des régimes privés d’assurance-maladie au Canada
  • Des produits biologiques ultérieurs (PBU)

Announcing ACE “JointHealth™ shareables”

JointHealth™ shareables – Check it out, and feel free to share!

Whether it is with an infographic, video, or on-line booklet, ACE looks for new, user-friendly ways to share information to help its members, subscribers and visitors stay current with popular arthritis and related healthcare topics and issues. With today’s launch of JointHealth™ shareables, we are giving you all three in one convenient spot. Each JointHealth™ shareable will cover a specific topic of interest identified by you, our reader and on-line visitor.

The first two JointHealth™ shareables are:

  • Private Health Insurance in Canada
  • Subsequent Entry Biologics (SEBs)

Qu’est-ce que le comité ACE a fait pour vous dernièrement

Flip Calendar FrenchVoici ce à quoi nous avons travaillé.

Journée mondiale de l’arthrite auto-immune

Organisée par la Fondation internationale pour l’arthrite auto-immune, la Journée mondiale de l’arthrite auto-immune réunissait une douzaine d’organisations sans but lucratif, de défenseurs du dossier de l’arthrite et d’experts du monde entier pour fournir de l’information éducative et de sensibilisation aux patients, à leurs soignants et au grand public. Le comité ACE a participé à cette course mondiale virtuelle et a poursuivi en ligne le dialogue sur l’arthrite. Continue reading

What has ACE done for you lately?

Calendar Flip JuneWhat has ACE done for you lately? Here’s what we’ve been working on.

World Autoimmune Arthritis Day

Hosted by the International Foundation for Autoimmune Arthritis, the World Autoimmune Arthritis Day united dozen of nonprofits, advocates, and experts from around the world to provide educational and awareness information to patients, their supporters, and the general public. ACE participated in this virtual global race and expanded the arthritis conversation online. Continue reading

ACE goes to Saskatoon for the 2015 CADTH Symposium

ACE goes to Saskatoon for the 2015 CADTH Symposium

Making arthritis news: Sharing the latest from the Paris of the Prairies 

CADTH 2015 PosterArthritis Consumer Experts (ACE) will be in Saskatoon, the “Paris of the Prairies”, to attend the 2015 CADTH Symposium at TCU Place. The meeting, between Sunday, April 12 and Tuesday, April 14, will bring together producers and users of evidence-based information on drugs and health technologies to learn about, collaborate and share the latest advances in health research and care.  Each year, the symposium attracts an estimated 650 delegates from key sectors, including Health Technology Assessment (HTA) producers, health economists, government, universities, healthcare providers, industry and patient groups.  Continue reading

JointHealth™ monthly – The JointHealth™ Medications Guide issue

Annual JointHealth™ Medications Guide: A consumer’s guide to arthritis medications

The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations 

Picture of JHM MarchThis year’s JointHealth™ Medications Guide gives you, our member, subscriber and on-line visitor concise, fact-based information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Feature articles about new medications and scientific advances that give a deeper understanding of the importance of timely initiation of medication therapy in appropriate doses, and a patient’s perspective on the therapy conversation, are key pieces that lead toward “personalized medicine”.

Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, spondyloarthritis, (systemic) juvenile idiopathic arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.

In this JointHealth™ monthly, you will also find:

  • An explanation of a new targeted small molecule medication and a subsequent entry biologic approved in Canada in 2014.
  • An interview with Alison Hoens, a woman living with rheumatoid arthritis, about therapy choices.
  • A history of methotrexate as an arthritis treatment.
  • Emerging research in the field of personalized medicine.